Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Pickles, T, Alten, R, Boers, M, Bykerk, V, Christensen, J, Christensen, R, van Hoogstraten, H, Simon, LS, Tam, L-S & Choy, EH 2019, 'Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group' Journal of Rheumatology, bind 46, nr. 10, s. 1406-1408. https://doi.org/10.3899/jrheum.181054

APA

Pickles, T., Alten, R., Boers, M., Bykerk, V., Christensen, J., Christensen, R., ... Choy, E. H. (2019). Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group. Journal of Rheumatology, 46(10), 1406-1408. https://doi.org/10.3899/jrheum.181054

CBE

Pickles T, Alten R, Boers M, Bykerk V, Christensen J, Christensen R, van Hoogstraten H, Simon LS, Tam L-S, Choy EH. 2019. Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group. Journal of Rheumatology. 46(10):1406-1408. https://doi.org/10.3899/jrheum.181054

MLA

Vancouver

Author

Pickles, Tim ; Alten, Rieke ; Boers, Maarten ; Bykerk, Vivian ; Christensen, Jared ; Christensen, Robin ; van Hoogstraten, Hubert ; Simon, Lee S ; Tam, Lai-Shan ; Choy, Ernest H. / Adaptive Trial Designs in Rheumatology : Report from the OMERACT Special Interest Group. I: Journal of Rheumatology. 2019 ; Bind 46, Nr. 10. s. 1406-1408.

Bibtex

@article{099bd629473c4d3198d216d27f7da06f,
title = "Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group",
abstract = "OBJECTIVE: Adaptive trial design was developed initially for oncology to improve trial efficiency. If optimized for rheumatology, it may improve trial efficiency by reducing sample size and time.METHODS: A systematic review assessed design of phase II clinical trials in rheumatoid arthritis.RESULTS: Fifty-six trials were reviewed. Most trials had 4 groups (1 control and 3 intervention), with an average group size of 34 patients. American College of Rheumatology 20 measured at 16 weeks was the most commonly used primary endpoint.CONCLUSION: The next step is to undertake a systematic review of adaptive designs used in early-phase trials in nonrheumatic conditions.",
author = "Tim Pickles and Rieke Alten and Maarten Boers and Vivian Bykerk and Jared Christensen and Robin Christensen and {van Hoogstraten}, Hubert and Simon, {Lee S} and Lai-Shan Tam and Choy, {Ernest H}",
year = "2019",
month = "10",
doi = "10.3899/jrheum.181054",
language = "English",
volume = "46",
pages = "1406--1408",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology Publishing Co. Ltd",
number = "10",

}

RIS

TY - JOUR

T1 - Adaptive Trial Designs in Rheumatology

T2 - Report from the OMERACT Special Interest Group

AU - Pickles, Tim

AU - Alten, Rieke

AU - Boers, Maarten

AU - Bykerk, Vivian

AU - Christensen, Jared

AU - Christensen, Robin

AU - van Hoogstraten, Hubert

AU - Simon, Lee S

AU - Tam, Lai-Shan

AU - Choy, Ernest H

PY - 2019/10

Y1 - 2019/10

N2 - OBJECTIVE: Adaptive trial design was developed initially for oncology to improve trial efficiency. If optimized for rheumatology, it may improve trial efficiency by reducing sample size and time.METHODS: A systematic review assessed design of phase II clinical trials in rheumatoid arthritis.RESULTS: Fifty-six trials were reviewed. Most trials had 4 groups (1 control and 3 intervention), with an average group size of 34 patients. American College of Rheumatology 20 measured at 16 weeks was the most commonly used primary endpoint.CONCLUSION: The next step is to undertake a systematic review of adaptive designs used in early-phase trials in nonrheumatic conditions.

AB - OBJECTIVE: Adaptive trial design was developed initially for oncology to improve trial efficiency. If optimized for rheumatology, it may improve trial efficiency by reducing sample size and time.METHODS: A systematic review assessed design of phase II clinical trials in rheumatoid arthritis.RESULTS: Fifty-six trials were reviewed. Most trials had 4 groups (1 control and 3 intervention), with an average group size of 34 patients. American College of Rheumatology 20 measured at 16 weeks was the most commonly used primary endpoint.CONCLUSION: The next step is to undertake a systematic review of adaptive designs used in early-phase trials in nonrheumatic conditions.

U2 - 10.3899/jrheum.181054

DO - 10.3899/jrheum.181054

M3 - Journal article

VL - 46

SP - 1406

EP - 1408

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 10

ER -

ID: 58098123